Journals / Ege Pediatri Bülteni / 2002 / Cilt: 9 - Sayı: 3

The measles seroprevalance in a group of children in Manisa city

Manisa ilinde seçilmiş bir grup çocukta kızamik seroprevalansı

Pages
117–121
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Overall seroprevalence was found as 89.5%; in children aged 9 to 11 years the seropositivity was found as 82%, and those older than 12 years it was found as 89%.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Measles is highly contagious disease, preventable by vaccine and it is still one of the common cause of morbidity and mortality in many countries.
📊
Key Findings & Data:In this study, measles IgG antibody in 656 children (aged nine months to 18 years) in Manisa were tested for existence of the measles IgG antibody by using micro ELISA method.
💡
Conclusion & Impact:Overall seroprevalence was found as 89.5%; in children aged 9 to 11 years the seropositivity was found as 82%, and those older than 12 years it was found as 89%.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Measles is highly contagious disease, preventable by vaccine and it is still one of the common cause of morbidity and mortality in many countries. In this study, measles IgG antibody in 656 children (aged nine months to 18 years) in Manisa were tested for existence of the measles IgG antibody by using micro ELISA method. Overall seroprevalence was found as 89.5%; in children aged 9 to 11 years the seropositivity was found as 82%, and those older than 12 years it was found as 89%. These results show that the vaccination programme at 9 months and 7 years should be continued. However, the second dose of measles vaccine has been recently started and applied only to 7 year old children attending primary school in our country, so, its efficacy is limited. Therefore the second dose of measles vaccine should be given to all children.

Özet

Kızamık, birçok ülkede halen morbidite ve mortalite nedeni olan, aşıyla önlenebilir özellikte oldukça bulaşıcı bir hastalıktır. Manisa ilinde Ocak 2000 - Haziran 2,001 tarihleri arasında 9 ay-18 yaş arası toplam 656 olguda mikro El A yöntemi kullanarak Kızamık IgG antikor pozitifliğini araştırdığımız bu çalışmada 9-12 ay arası bebeklerde seropozitifliğin % 100, 13 ay -5 yaş grubunda ve 6-11 yaş grubunda % 82 olduğu ve 12 yaştan sonra % 89'a ulaştığı, toplam seropozitifliğin ise % 89.5 olduğu saptanmıştır. Bu durum, kızamık aşılamasının ikinci dozunun gerekli olduğunu göstermekte olup seropozitiflik yaşla artış göstermekle birlikte yinede % 10 oranında kızamık virüsüne duyarlı olguların var olduğu unutulmamalı ve okulda aşılaması yapılamayan daha büyük yaşlardaki çocuk ve adolesanların ikinci doz kızamık aşıları uygulanmalıdır. Bu sonuçlar ülkemizde 9. ayda ve 7 yaşında yapılan aşı uygulamalarının sürdürülmesi gerektiğini göstermektedir. Ancak 7 yaşta yapılan uygulama henüz yeni olduğundan ve yalnızca öğrencilerle sınırlı kaldığından tüm çocukların ikinci doz kızamık aşısının yapılması sağlanmalıdır.

🔖

Cite This Article

TOSUN, Y. S., ERTAN, P., KASIRGA, E., LÜLECİ, E. (2022). The measles seroprevalance in a group of children in Manisa city. Ege Pediatri Bülteni, Cilt: 9 - Sayı: 3, 117–121. https://ajindex.com/articles/495845

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Melish ME, Hotez P. Measles (Rubeola). İn: Katz SL, Gershon AA, Hotez P, eds. Krugman's Infectious Diseases of Children. St.Louis: Mosby-Year Book Inc., 1998: 247-253
  2. Gershon AA. Measles virus (rubeola). In: Mandeil GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases. Newyork: Churchill Livingstone, 2000:1801-1809
  3. World Health Organization, Expanded Programme on Immunization. Meeting on advances in measles elimination:coclusions and recommendations. WW Epidemiol Rec 1996; 71: 305-309
  4. Centers for Disease Control and Prevention. Measles prevention: recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR 1989; 38: 1 -18
  5. Averhoff FM, Williams WW, Hadler SC. Immunization of adolescents: recommendations of the Advisory Committee on Immunization Practices, the American Academy of Pediatrics,the American Academy of Family Physicians, and the American Medical Association. J Sch Health 1997; 67: 298-303
  6. Watson JC, Hadler SC, Dykewicz CA, Reef S, Philips L. Measles, mumps, and rubella-vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps:recommendations of the Advisory on Immunization Practices (ACIP) MMWR Morb Mortal Wkly Rep 1998; 47(RR-8): 1-57
  7. World Health Organization. Measles-progress towards global control and and regional elimination,1998-1999. Wkly Epidemiol Rec 1999; 74: 429-440
  8. Wairagkar NS, Shaikh NJ, Udavant P, Banerjee K. Isolation of measles virus below 4 months of age during an outbreake in Purie.lndia. Lancet 1999; 353: 2026-2029
  9. Khuri-Bulos NA. Measles in Jordan: a protype of the problems with measles in developing countries. Pediatr Infect Dis J 1995; 14:22-26. 10 Orenstein WA, Markowitz L, Atkinson WL, Hinman AR. Worldwide measles prevention. Isr J Med Sci 30; 1994: 469-481
  10. Babaniyi OA, Parakoyi DB, Aiyedeun BA, Bello MA. Loss of maternally-acquired measles antibody during infancy in Horin, Nigeria. J Trop Pediatr 1995; 41:115-117
  11. Centers for Disease Control and Prevention. News: partnership for measles eradication in the Americas by the year 2000 Pan American Health Organization and the CDC of the United States. MMWR Morb Mortal Wkly Rep 2000 Dec 15; 49:1116-1118
  12. Robertson SE, Mayans MV, El-Husseiny A, Clemens JD, Ivanoff B.The WHO Vaccine Trial Registry. Vaccine 2001; 12: 31-41 14. Cutts FT, Bartoloni A, Guglielmetti P, et al. Response to measles revaccination among Bolivian school-aged c